In addition, the novel non‐steroidal, selective MR antagonist finerenone has shown a reduction of the risk of cardiovascular events in individuals with type 2 diabetes and chronic kidney disease compared with placebo (Agarwal et al., 2022; Barrera‐Chimal et al., 2022). Here, NR3C2 is linked to type 2 diabetes mellitus.